Trial Condition(s):

Prostate Cancer

A study in which non-metastatic castration-resistant prostate cancer (nmCRPC) patients for whom a decision to treat with darolutamide has been made before enrollment are observed and certain outcomes are described (DAROL)

Bayer Identifier:

20590

ClinicalTrials.gov Identifier:

NCT04122976

EudraCT Number:

Not Available

EU CT Number:

Not Available

Recruitment Complete

Trial Purpose

The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.

Inclusion Criteria
- Men over the age of 18 years
- Histologically or cytologically confirmed adenocarcinoma CRPC defined by disease progression despite ADT and may present as a confirmed rise in serum PSA levels (as defined by PCWG3: Rising PSA values at a minimum of 1-week intervals, and a baseline PSA value ≥ 1.0 ng/mL). For patients with a prior ARi treatment (Enzalutamide or Apalutamide), there is no baseline PSA value required
- No evidence of metastasis based on conventional imaging. An imaging assessment needs to be obtained prior to the 1st dose of darolutamide. For patients with a prior ARi treatment (Enzalutamide or Apalutamide) for nmCRPC, M0 status with no evidence of disease progression should be confirmed within 3 months of ARi discontinuation
- Decision to initiate treatment with darolutamide was made as per investigator’s routine treatment practice prior to enrollment in the study
- Signed informed consent
- Life expectancy of ≥3 months
- For a patient with a prior ARi treatment (Enzalutamide or Apalutamide) for nmCRPC for less than one year, all toxic effects from prior use of any ARi treatment have to be resolved at the time of enrollment and prior to the 1st dose of darolutamide
Exclusion Criteria
- Participation in an investigational program with interventions outside of routine clinical practice
- Contraindications according to the local marketing authorization 
- Previous treatment with darolutamide (more than 3 days prior to enrollment)
- Patient with a prior ARi treatment (Enzalutamide or Apalutamide) for nmCRPC for more than one year

Trial Summary

Enrollment Goal
805
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nubeqa (Darolutamide, BAY1841788)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Locations
Locations

Many Locations

Many Locations, Argentina

Locations

Many Locations

Many Locations, Austria

Locations

Many Locations

Many Locations, Belgium

Locations

Many Locations

Many Locations, Brazil

Locations

Many Locations

Many Locations, Canada

Locations

Many Locations

Many Locations, China

Locations

Many Locations

Many Locations, Colombia

Locations

Many Locations

Many Locations, Germany

Locations

Many Locations

Many Locations, Denmark

Locations

Many Locations

Many Locations, Spain

Locations

Many Locations

Many Locations, France

Locations

Many Locations

Many Locations, Greece

Locations

Many Locations

Many Locations, Hong Kong, China

Locations

Many Locations

Many Locations, Italy

Locations

Many Locations

Many Locations, Japan

Locations

Many Locations

Many Locations, Mexico

Locations

Many Locations

Many Locations, Russia

Locations

Many Locations

Many Locations, Taiwan, China

Locations

Dukes Cancer Intitute Center for Prostate and Urologic Cancers

Durham, United States, 27710

Locations

Arizona Institute of Urology

Tucson, United States, 85704

Locations

Associated Medical Professional Urology

Syracuse, United States, 13210

Locations

University of Washington

Seattle, United States, 98101

Locations

Urology San Antonio

San Antonio, United States, 78229

Locations

Urology Centers of Alabama

Homewood, United States, 35209

Locations

First Urology, PSC

Jeffersonville, United States, 47130

Locations

Keystone Urology Specialists

Lancaster, United States, 17601

Locations

Wichita Urology Group

Wichita, United States, 67206

Locations

Genesis Comprehensive Prostate Cancer Center

San Diego, United States, 92123

Locations

New Jersey Urology

Englewood, United States, 07631

Locations

Manatee Medical Research Institute

Bradenton, United States, 34205

Locations

Associated Urologists of NC

Raleigh, United States, 27612

Locations

Oregon Urology Institutue

Springfield, United States, 01106

Locations

Vanderbilt University Medical Center

Nashville, United States, 37203

Locations

Baylor Scott & White Medical Center - Temple

Temple, United States, 76508

Locations

Urology of Virginia

Virginia Beach, United States, 23462

Locations

Integrated Medical Professionals, PLLC

North New Hyde Park, United States, 11042

Locations

Advanced Urology Institute

Daytona Beach, United States, 32114

Locations

MultiCare Institute for Research & Innovation

Tacoma, United States, 98405

Locations

Premier Medical Group of the Hudson Valley, PC

Poughkeepsie, United States, 12603

Locations

Southcoast Centers for Cancer Care

Fairhaven, United States, 02719

Locations

The Urology Center of Colorado

Denver, United States, 80211

Locations

Beacon Cancer Care

Beacon, United States, 83814

Locations

Research by Design, LLC

Chicago, United States, 60643

Trial Design